Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Effects of vitamin D on axonal damage during de- and remyelination in the cuprizone model.

Nystad AE, Torkildsen Ø, Wergeland S.

J Neuroimmunol. 2018 Aug 15;321:61-65. doi: 10.1016/j.jneuroim.2018.05.016. Epub 2018 Jun 1.

PMID:
29957389
2.

α-Linolenic acid is associated with MRI activity in a prospective cohort of multiple sclerosis patients.

Bjornevik K, Myhr KM, Beiske A, Bjerve KS, Holmøy T, Hovdal H, Midgard R, Riise T, Wergeland S, Torkildsen Ø.

Mult Scler. 2018 May 1:1352458518779925. doi: 10.1177/1352458518779925. [Epub ahead of print]

PMID:
29862891
3.

Severe multiple sclerosis reactivation after gonadotropin treatment.

Torkildsen Ø, Holmøy T, Myhr KM.

Mult Scler Relat Disord. 2018 May;22:38-40. doi: 10.1016/j.msard.2018.02.031. Epub 2018 Mar 6.

PMID:
29525298
4.

Neurofilament light chain predicts disease activity in relapsing-remitting MS.

Varhaug KN, Barro C, Bjørnevik K, Myhr KM, Torkildsen Ø, Wergeland S, Bindoff LA, Kuhle J, Vedeler C.

Neurol Neuroimmunol Neuroinflamm. 2017 Nov 28;5(1):e422. doi: 10.1212/NXI.0000000000000422. eCollection 2018 Jan.

5.

Glitazone use associated with reduced risk of Parkinson's disease.

Brakedal B, Flønes I, Reiter SF, Torkildsen Ø, Dölle C, Assmus J, Haugarvoll K, Tzoulis C.

Mov Disord. 2017 Nov;32(11):1594-1599. doi: 10.1002/mds.27128. Epub 2017 Sep 1.

6.

An update on cladribine for relapsing-remitting multiple sclerosis.

Holmøy T, Torkildsen Ø, Myhr KM.

Expert Opin Pharmacother. 2017 Oct;18(15):1627-1635. doi: 10.1080/14656566.2017.1372747. Epub 2017 Sep 11. Review.

PMID:
28858531
7.

1,25-Dihydroxyvitamin-D3 induces brain proteomic changes in cuprizone mice during remyelination involving calcium proteins.

Oveland E, Nystad A, Berven F, Myhr KM, Torkildsen Ø, Wergeland S.

Neurochem Int. 2018 Jan;112:267-277. doi: 10.1016/j.neuint.2017.08.008. Epub 2017 Aug 14.

PMID:
28818673
8.

Re: Familieplanlegging, graviditet og amming ved multippel sklerose.

Holmøy T, Torkildsen Ø.

Tidsskr Nor Laegeforen. 2017 Feb 21;137(4):259. doi: 10.4045/tidsskr.17.0054. eCollection 2017 Feb. Norwegian. No abstract available.

PMID:
28225223
Free Article
9.

Family planning, pregnancy and breastfeeding in multiple sclerosis.

Holmøy T, Torkildsen Ø.

Tidsskr Nor Laegeforen. 2016 Nov 8;136(20):1726-1729. eCollection 2016 Nov. Review. English, Norwegian.

10.

The Brain Proteome of the Ubiquitin Ligase Peli1 Knock-Out Mouse during Experimental Autoimmune Encephalomyelitis.

Lereim RR, Oveland E, Xiao Y, Torkildsen Ø, Wergeland S, Myhr KM, Sun SC, Berven FS.

J Proteomics Bioinform. 2016 Sep;9(9):209-219. Epub 2016 Sep 12.

11.

In-Depth Cerebrospinal Fluid Quantitative Proteome and Deglycoproteome Analysis: Presenting a Comprehensive Picture of Pathways and Processes Affected by Multiple Sclerosis.

Kroksveen AC, Guldbrandsen A, Vaudel M, Lereim RR, Barsnes H, Myhr KM, Torkildsen Ø, Berven FS.

J Proteome Res. 2017 Jan 6;16(1):179-194. doi: 10.1021/acs.jproteome.6b00659. Epub 2016 Oct 26.

PMID:
27728768
12.

[Thrombolytic therapy and thrombectomy in unknown stroke onset].

Kvistad CE, Torkildsen Ø, Næss H, Svalestad S.

Tidsskr Nor Laegeforen. 2016 Sep 13;136(16):1363. doi: 10.4045/tidsskr.16.0269. eCollection 2016 Sep. Norwegian. No abstract available.

13.

No association of tobacco use and disease activity in multiple sclerosis.

Kvistad S, Myhr KM, Holmøy T, Benth JŠ, Løken-Amsrud KI, Wergeland S, Beiske AG, Bjerve KS, Hovdal H, Lilleås F, Midgard R, Pedersen T, Bakke SJ, Torkildsen Ø.

Neurol Neuroimmunol Neuroinflamm. 2016 Jul 14;3(4):e260. doi: 10.1212/NXI.0000000000000260. eCollection 2016 Aug.

14.

Effect of high-dose vitamin D3 supplementation on antibody responses against Epstein-Barr virus in relapsing-remitting multiple sclerosis.

Røsjø E, Lossius A, Abdelmagid N, Lindstrøm JC, Kampman MT, Jørgensen L, Sundström P, Olsson T, Steffensen LH, Torkildsen Ø, Holmøy T.

Mult Scler. 2017 Mar;23(3):395-402. doi: 10.1177/1352458516654310. Epub 2016 Jul 11.

PMID:
27325604
15.

Level of education and multiple sclerosis risk over a 50-year period: Registry-based sibling study.

Bjørnevik K, Riise T, Benjaminsen E, Celius EG, Dahl OP, Kampman MT, Løken-Amsrud KI, Midgard R, Myhr KM, Torkildsen Ø, Vatne A, Grytten N.

Mult Scler. 2017 Feb;23(2):213-219. doi: 10.1177/1352458516646863. Epub 2016 Jul 11.

16.

Vitamin D, HLA-DRB1 and Epstein-Barr virus antibody levels in a prospective cohort of multiple sclerosis patients.

Wergeland S, Myhr KM, Løken-Amsrud KI, Beiske AG, Bjerve KS, Hovdal H, Midgard R, Kvistad SS, Holmøy T, Riise T, Torkildsen Ø.

Eur J Neurol. 2016 Jun;23(6):1064-70. doi: 10.1111/ene.12986. Epub 2016 Mar 21.

PMID:
26998820
17.

Botulinum Toxin as Monotherapy in Symptomatic Trigeminal Neuralgia.

Lunde HM, Torkildsen Ø, Bø L, Bertelsen AK.

Headache. 2016 Jun;56(6):1035-9. doi: 10.1111/head.12791. Epub 2016 Mar 17.

PMID:
26992044
18.

Detection of varicella-zoster virus DNA during medullary and brainstem relapses in multiple sclerosis.

Torkildsen Ø, Power Ø, Storstein A.

BMJ Case Rep. 2016 Feb 23;2016. pii: bcr2016214555. doi: 10.1136/bcr-2016-214555.

19.

Label-free analysis of human cerebrospinal fluid addressing various normalization strategies and revealing protein groups affected by multiple sclerosis.

Opsahl JA, Vaudel M, Guldbrandsen A, Aasebø E, Van Pesch V, Franciotta D, Myhr KM, Barsnes H, Berle M, Torkildsen Ø, Kroksveen AC, Berven FS.

Proteomics. 2016 Apr;16(7):1154-65. doi: 10.1002/pmic.201500284.

PMID:
26841090
20.

Can vitamin D reduce inflammation in relapsing-remitting multiple sclerosis?

Holmøy T, Torkildsen Ø.

Expert Rev Neurother. 2016;16(3):233-5. doi: 10.1586/14737175.2016.1146134. Epub 2016 Feb 12. No abstract available.

PMID:
26796244
21.

Disease-modifying treatments for multiple sclerosis - a review of approved medications.

Torkildsen Ø, Myhr KM, Bø L.

Eur J Neurol. 2016 Jan;23 Suppl 1:18-27. doi: 10.1111/ene.12883. Review.

22.

Body mass index influence interferon-beta treatment response in multiple sclerosis.

Kvistad SS, Myhr KM, Holmøy T, Šaltytė Benth J, Wergeland S, Beiske AG, Bjerve KS, Hovdal H, Lilleås F, Midgard R, Pedersen T, Bakke SJ, Michelsen AE, Aukrust P, Ueland T, Sagen JV, Torkildsen Ø.

J Neuroimmunol. 2015 Nov 15;288:92-7. doi: 10.1016/j.jneuroim.2015.09.008. Epub 2015 Sep 26.

PMID:
26531700
23.

Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis.

Røsjø E, Steffensen LH, Jørgensen L, Lindstrøm JC, Šaltytė Benth J, Michelsen AE, Aukrust P, Ueland T, Kampman MT, Torkildsen Ø, Holmøy T.

J Neurol. 2015 Dec;262(12):2713-21. doi: 10.1007/s00415-015-7902-5. Epub 2015 Oct 1.

PMID:
26429571
24.

Reply to comments on the review article 'Time trends in the incidence and prevalence of multiple sclerosis in Norway during eight decades'.

Grytten N, Torkildsen Ø, Myhr KM.

Acta Neurol Scand. 2015 Nov;132(5):368-9. doi: 10.1111/ane.12488. Epub 2015 Sep 15. No abstract available.

PMID:
26369381
25.

Fingolimod does not enhance cerebellar remyelination in the cuprizone model.

Alme MN, Nystad AE, Bø L, Myhr KM, Vedeler CA, Wergeland S, Torkildsen Ø.

J Neuroimmunol. 2015 Aug 15;285:180-6. doi: 10.1016/j.jneuroim.2015.06.006. Epub 2015 Jun 19.

26.

Quantitative proteomics suggests decrease in the secretogranin-1 cerebrospinal fluid levels during the disease course of multiple sclerosis.

Kroksveen AC, Jaffe JD, Aasebø E, Barsnes H, Bjørlykke Y, Franciotta D, Keshishian H, Myhr KM, Opsahl JA, van Pesch V, Teunissen CE, Torkildsen Ø, Ulvik RJ, Vethe H, Carr SA, Berven FS.

Proteomics. 2015 Oct;15(19):3361-9. doi: 10.1002/pmic.201400142. Epub 2015 Sep 8.

PMID:
26152395
27.

Time trends in the incidence and prevalence of multiple sclerosis in Norway during eight decades.

Grytten N, Torkildsen Ø, Myhr KM.

Acta Neurol Scand. 2015;132(199):29-36. doi: 10.1111/ane.12428. Review.

28.

The Norwegian Multiple Sclerosis Registry and Biobank.

Myhr KM, Grytten N, Torkildsen Ø, Wergeland S, Bø L, Aarseth JH.

Acta Neurol Scand. 2015;132(199):24-8. doi: 10.1111/ane.12427. Review.

PMID:
26046555
29.

WT1 and interferon-β-vitamin D association in MS: a longitudinal study.

Holmøy T, Esbensen QY, Torkildsen Ø, Wergeland S, Bjerve KS, Beiske AG, Midgard R, Šaltytė-Benth J, Hovdal H, Myhr KM.

Acta Neurol Scand. 2016 Apr;133(4):309-12. doi: 10.1111/ane.12448. Epub 2015 Jun 2.

PMID:
26037530
30.

Impact of the environment on multiple sclerosis.

Løken-Amsrud KI, Lossius A, Torkildsen Ø, Holmøy T.

Tidsskr Nor Laegeforen. 2015 May 19;135(9):856-60. doi: 10.4045/tidsskr.14.0751. eCollection 2015 May 19. Review. English, Norwegian.

31.

Vitamin D status and effect of interferon-β1a treatment on MRI activity and serum inflammation markers in relapsing-remitting multiple sclerosis.

Røsjø E, Myhr KM, Løken-Amsrud KI, Bakke SJ, Beiske AG, Bjerve KS, Hovdal H, Lilleås F, Midgard R, Pedersen T, Šaltytė Benth J, Torkildsen Ø, Wergeland S, Michelsen AE, Aukrust P, Ueland T, Holmøy T.

J Neuroimmunol. 2015 Mar 15;280:21-8. doi: 10.1016/j.jneuroim.2015.02.001. Epub 2015 Feb 11.

PMID:
25773151
32.

Magnetization transfer ratio does not correlate to myelin content in the brain in the MOG-EAE mouse model.

Fjær S, Bø L, Myhr KM, Torkildsen Ø, Wergeland S.

Neurochem Int. 2015 Apr-May;83-84:28-40. doi: 10.1016/j.neuint.2015.02.006. Epub 2015 Mar 2.

33.

Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study.

Kuhle J, Disanto G, Dobson R, Adiutori R, Bianchi L, Topping J, Bestwick JP, Meier UC, Marta M, Dalla Costa G, Runia T, Evdoshenko E, Lazareva N, Thouvenot E, Iaffaldano P, Direnzo V, Khademi M, Piehl F, Comabella M, Sombekke M, Killestein J, Hegen H, Rauch S, D'Alfonso S, Alvarez-Cermeño JC, Kleinová P, Horáková D, Roesler R, Lauda F, Llufriu S, Avsar T, Uygunoglu U, Altintas A, Saip S, Menge T, Rajda C, Bergamaschi R, Moll N, Khalil M, Marignier R, Dujmovic I, Larsson H, Malmestrom C, Scarpini E, Fenoglio C, Wergeland S, Laroni A, Annibali V, Romano S, Martínez AD, Carra A, Salvetti M, Uccelli A, Torkildsen Ø, Myhr KM, Galimberti D, Rejdak K, Lycke J, Frederiksen JL, Drulovic J, Confavreux C, Brassat D, Enzinger C, Fuchs S, Bosca I, Pelletier J, Picard C, Colombo E, Franciotta D, Derfuss T, Lindberg R, Yaldizli Ö, Vécsei L, Kieseier BC, Hartung HP, Villoslada P, Siva A, Saiz A, Tumani H, Havrdová E, Villar LM, Leone M, Barizzone N, Deisenhammer F, Teunissen C, Montalban X, Tintoré M, Olsson T, Trojano M, Lehmann S, Castelnovo G, Lapin S, Hintzen R, Kappos L, Furlan R, Martinelli V, Comi G, Ramagopalan SV, Giovannoni G.

Mult Scler. 2015 Jul;21(8):1013-24. doi: 10.1177/1352458514568827. Epub 2015 Feb 13.

PMID:
25680984
34.

Cerebrospinal fluid proteomics in multiple sclerosis.

Kroksveen AC, Opsahl JA, Guldbrandsen A, Myhr KM, Oveland E, Torkildsen Ø, Berven FS.

Biochim Biophys Acta. 2015 Jul;1854(7):746-56. doi: 10.1016/j.bbapap.2014.12.013. Epub 2014 Dec 16. Review.

PMID:
25526888
35.

Reply to comment: Month of birth and risk of multiple sclerosis: confounding and adjustments.

Torkildsen O, Aarseth J, Celius EG, Holmøy T, Kampman MT, Løken-Amsrud KI, Midgard R, Myhr KM, Riise T, Grytten N.

Ann Clin Transl Neurol. 2014 May;1(5):376-7. doi: 10.1002/acn3.56. Epub 2014 Apr 10. No abstract available.

36.

Month of birth and risk of multiple sclerosis: confounding and adjustments.

Torkildsen O, Aarseth J, Benjaminsen E, Celius E, Holmøy T, Kampman MT, Løken-Amsrud K, Midgard R, Myhr KM, Riise T, Grytten N.

Ann Clin Transl Neurol. 2014 Feb;1(2):141-4. doi: 10.1002/acn3.37. Epub 2014 Feb 4.

37.

Treatment-resistant immune thrombocytopenic purpura associated with LDN use in a patient with MS.

Torkildsen O, Myhr KM, Wergeland S.

Neurol Neuroimmunol Neuroinflamm. 2014 Aug 21;1(3):e25. doi: 10.1212/NXI.0000000000000025. eCollection 2014 Oct. No abstract available.

38.

[Re: Vitamin D--how much is enough, and is more better for your health?].

Holmøy T, Løken-Amsrud K, Kampman MT, Torkildsen Ø, Myhr KM.

Tidsskr Nor Laegeforen. 2014 May 27;134(10):1024-5. doi: 10.4045/tidsskr.14.0618. eCollection 2014 May 27. Norwegian. No abstract available.

39.

Effect of high-dose 1.25 dihydroxyvitamin D3 on remyelination in the cuprizone model.

Nystad AE, Wergeland S, Aksnes L, Myhr KM, Bø L, Torkildsen O.

APMIS. 2014 Dec;122(12):1178-86. doi: 10.1111/apm.12281. Epub 2014 May 26.

PMID:
24862867
40.

Antibodies to Epstein-Barr virus and MRI disease activity in multiple sclerosis.

Kvistad S, Myhr KM, Holmøy T, Bakke S, Beiske AG, Bjerve KS, Hovdal H, Løken-Amsrud KI, Lilleås F, Midgard R, Njølstad G, Pedersen T, Benth JŠ, Wergeland S, Torkildsen O.

Mult Scler. 2014 Dec;20(14):1833-40. doi: 10.1177/1352458514533843. Epub 2014 May 19.

PMID:
24842958
41.

Increasing serum levels of vitamin A, D and E are associated with alterations of different inflammation markers in patients with multiple sclerosis.

Røsjø E, Myhr KM, Løken-Amsrud KI, Bakke SJ, Beiske AG, Bjerve KS, Hovdal H, Lilleås F, Midgard R, Pedersen T, Benth JS, Torkildsen Ø, Wergeland S, Michelsen AE, Aukrust P, Ueland T, Holmøy T.

J Neuroimmunol. 2014 Jun 15;271(1-2):60-5. doi: 10.1016/j.jneuroim.2014.03.014. Epub 2014 Mar 24.

PMID:
24713402
42.

Deep gray matter demyelination detected by magnetization transfer ratio in the cuprizone model.

Fjær S, Bø L, Lundervold A, Myhr KM, Pavlin T, Torkildsen O, Wergeland S.

PLoS One. 2013 Dec 30;8(12):e84162. doi: 10.1371/journal.pone.0084162. eCollection 2013. Erratum in: PLoS One. 2014;9(10):e111828.

43.

[Neuromyelitis optica].

Kvistad SA, Wergeland S, Torkildsen Ø, Myhr KM, Vedeler CA.

Tidsskr Nor Laegeforen. 2013 Oct 15;133(19):2057-61. doi: 10.4045/tidsskr.13.0608. Review. Norwegian.

44.

Inflammation markers in multiple sclerosis: CXCL16 reflects and may also predict disease activity.

Holmøy T, Løken-Amsrud KI, Bakke SJ, Beiske AG, Bjerve KS, Hovdal H, Lilleås F, Midgard R, Pedersen T, Saltytė Benth J, Torkildsen O, Wergeland S, Myhr KM, Michelsen AE, Aukrust P, Ueland T.

PLoS One. 2013 Sep 19;8(9):e75021. doi: 10.1371/journal.pone.0075021. eCollection 2013.

45.

Peli1 promotes microglia-mediated CNS inflammation by regulating Traf3 degradation.

Xiao Y, Jin J, Chang M, Chang JH, Hu H, Zhou X, Brittain GC, Stansberg C, Torkildsen Ø, Wang X, Brink R, Cheng X, Sun SC.

Nat Med. 2013 May;19(5):595-602. doi: 10.1038/nm.3111. Epub 2013 Apr 21.

46.

No evidence of association between mutant alleles of the CYP27B1 gene and multiple sclerosis.

Ban M, Caillier S, Mero IL, Myhr KM, Celius EG, Aarseth J, Torkildsen Ø, Harbo HF, Oksenberg J, Hauser SL, Sawcer S, Compston A.

Ann Neurol. 2013 Mar;73(3):430-2. doi: 10.1002/ana.23833. Epub 2013 Feb 26.

47.

Alpha-tocopherol and MRI outcomes in multiple sclerosis--association and prediction.

Løken-Amsrud KI, Myhr KM, Bakke SJ, Beiske AG, Bjerve KS, Bjørnarå BT, Hovdal H, Lilleås F, Midgard R, Pedersen T, Benth JŠ, Torkildsen Ø, Wergeland S, Holmøy T.

PLoS One. 2013;8(1):e54417. doi: 10.1371/journal.pone.0054417. Epub 2013 Jan 22.

48.

Epstein-Barr virus in systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis—association and causation.

Lossius A, Johansen JN, Torkildsen Ø, Vartdal F, Holmøy T.

Viruses. 2012 Dec;4(12):3701-30. Review.

49.

Sex ratio of multiple sclerosis in persons born from 1930 to 1979 and its relation to latitude in Norway.

Kampman MT, Aarseth JH, Grytten N, Benjaminsen E, Celius EG, Dahl OP, Holmøy T, Løken-Amsrud K, Midgard R, Myhr KM, Risberg G, Vatne A, Torkildsen O.

J Neurol. 2013 Jun;260(6):1481-8. doi: 10.1007/s00415-012-6814-x. Epub 2013 Jan 6.

PMID:
23292231
50.

Fcγ receptors in Norwegian multiple sclerosis patients and healthy controls.

Gavasso S, Torkildsen Ø, Marøy TH, Ulvestad E, Myhr KM, Vedeler CA.

Acta Neurol Scand Suppl. 2012;(195):84-9. doi: 10.1111/ane.12026.

PMID:
23278662

Supplemental Content

Loading ...
Support Center